Trial Profile
Home Delivery of Pemetrexed as Maintenance Treatment in Patients Who Have Not Progressed after Induction Therapy for Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Feasibility Study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jul 2019
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jun 2013 Planned End Date changed from 1 Feb 2014 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 15 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.